Area of Study / Keywords
Colorectal cancer DNA repair Mucosal immunology Mismatch repair Intestinal microbiome Exosomes IgG Organoids Orthotopic tumor model Dendritic cells T cells Metastasis intestine microsatellite instability DNA damage immunity inflammation apoptosis cell stress colon intestinal epithelial cell (IEC) microbiota genotoxin homeostasis Tumor infiltrating lymphocytes (TILs) Orthotopic models
AboutDr. Kristi Baker is currently appointed as Associate Professor in the Department of Oncology in the Faculty of Medicine & Dentistry.
Colorectal cancer occurs when epithelial cells in the intestine start to grow uncontrollably. While many events need to take place to produce
The second element of cancer development that our lab studies
Our lab studies differences in how the specialized mucosal immune in the intestine sees
We are currently focused on answering questions in three major areas:
- What kinds of immune responses are associated with disruptions to different DNA repair pathways that produce different patterns of genomic instability?
- Are different kinds of microbial species living in the intestine (aka "the microbiota") associated with cancers having different underlying patterns of genomic instability? How do microbial metabolites and genotoxic substances alter a
- How does DNA damage resulting from chemotherapy and radiotherapy influence anti-tumor immunity? Is this related to the poor response rates of colorectal cancer patients
tonew forms of adjuvant immunotherapy?
We expect that our work will give the cancer community a better understanding of how
The course will provide an introduction to the basic science of oncology. Topics to be covered comprise: the genetic basis of cancer, including the role of proto-oncogenes and tumor suppressor genes; mechanisms of carcinogenesis and radiation-sensitivity, including DNA repair and cell cycle control; the molecular basis of tumor metastasis, including tumor cell invasion, extravasation and dormancy; the role of inflammation in cancer initiation and progression; angiogenesis; cancer genetics, and epigenetics; cell signaling; experimental therapeutics; cancer stem cells; drug-resistance; metabolism and palliation. Course offered in alternate (even-numbered) years. Prerequisites: BIOCH 200, and one of the following: BIOCH 320 or 330 or ONCOL 320.
Mosley S.R., Baker K.
STAR Protocols. 2022 March; 3 (1) 10.1016/j.xpro.2022.101165
Mowat C., Mosley S.R., Namdar A., Schiller D., Baker K.
JOURNAL OF EXPERIMENTAL MEDICINE. 2021 July; 218 (9) 10.1084/jem.20210108
Hubbard J.J., Pyzik M., Rath T., Kozicky L.K., Sand K.M.K., Gandhi A.K., Grevys A., Foss S., Menzies S.C., Glickman J.N., Fiebiger E., Roopenian D.C., Sandlie I., Andersen J.T., Sly L.M., Baker K., Blumberg R.S.
JOURNAL OF EXPERIMENTAL MEDICINE. 2020 October; 217 (10) 10.1084/JEM.20200359